Jul.16 — Johnson & Johnson Chief Financial Officer Joseph Wolk says the company is in active discussions with the European Union, Japan and the Bill & Melinda Gates Foundation to determine how much supply of its experimental coronavirus vaccine will be needed. He speaks with Bloomberg’s Alix Steel and Guy Johnson on “Bloomberg Markets.”
In This Story: markets
4 Recent Items: markets
In This Story: Vaccine
A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins.